MSD has welcomed the first European pricing and reimbursement recommendation for its rare disease drug Welireg (belzutifan) in Scotland, but is clearly disappointed that the product will not be appraised under NICE’s highly specialized technologies process in England.
Soctland’s health technology appraisal body, the SMC, has okayed Welireg for use on the National Health Service for adult patients with von Hippel-Lindau (VHL) disease who need treatment for VHL associated renal cell carcinoma, central nervous system hemangioblastomas, or
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?